Mahamaya Lifesciences Limited (BOM:544611)
India · Delayed Price · Currency is INR 175.00
0.00 (0.00%)
At close: Jun 15, 2026
Mahamaya Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 3,289 | 2,641 | 1,616 | 1,371 | 899.13 |
Other Revenue | - | 0.87 | - | 0.45 | 0.05 |
| 3,289 | 2,642 | 1,616 | 1,371 | 899.19 | |
Revenue Growth (YoY) | 24.46% | 63.54% | 17.83% | 52.50% | - |
Cost of Revenue | 2,748 | 2,267 | 1,391 | 1,184 | 752.95 |
Gross Profit | 540.34 | 374.97 | 224.48 | 186.77 | 146.24 |
Selling, General & Admin | 82.93 | 78.2 | 54.06 | 50.79 | 55.4 |
Other Operating Expenses | 122.24 | 49.54 | 36.39 | 38.95 | 26.62 |
Operating Expenses | 227.59 | 145.46 | 104.51 | 102.46 | 91.62 |
Operating Income | 312.75 | 229.51 | 119.96 | 84.31 | 54.62 |
Interest Expense | -81.39 | -55.12 | -46.04 | -26.33 | -15.8 |
Interest & Investment Income | - | 2.66 | 3.22 | 0.78 | 0.33 |
Currency Exchange Gain (Loss) | - | 9.1 | 4.56 | -5.88 | 0.1 |
Other Non Operating Income (Expenses) | 7.46 | -12.72 | -9.18 | -2.13 | -2.03 |
EBT Excluding Unusual Items | 238.82 | 173.43 | 72.52 | 50.76 | 37.21 |
Gain (Loss) on Sale of Assets | - | 0.19 | 0.18 | 0.21 | - |
Other Unusual Items | -0.04 | -1.1 | 1.58 | - | - |
Pretax Income | 238.78 | 172.52 | 74.28 | 50.96 | 37.21 |
Income Tax Expense | 73.54 | 44.4 | 20.52 | 13.46 | 9.98 |
Net Income | 165.23 | 128.12 | 53.76 | 37.51 | 27.23 |
Net Income to Common | 165.23 | 128.12 | 53.76 | 37.51 | 27.23 |
Net Income Growth | 28.97% | 138.31% | 43.34% | 37.72% | - |
Shares Outstanding (Basic) | 20 | 17 | 14 | 14 | 14 |
Shares Outstanding (Diluted) | 20 | 17 | 14 | 14 | 14 |
Shares Change (YoY) | 16.82% | 23.62% | - | - | - |
EPS (Basic) | 8.33 | 7.55 | 3.91 | 2.73 | 1.98 |
EPS (Diluted) | 8.33 | 7.55 | 3.91 | 2.73 | 1.98 |
EPS Growth | 10.40% | 92.78% | 43.36% | 37.88% | - |
Free Cash Flow | -383.32 | -83.49 | -249.73 | -17.7 | -11.07 |
Free Cash Flow Per Share | -19.32 | -4.92 | -18.18 | -1.29 | -0.81 |
Gross Margin | 16.43% | 14.19% | 13.89% | 13.62% | 16.26% |
Operating Margin | 9.51% | 8.69% | 7.42% | 6.15% | 6.08% |
Profit Margin | 5.02% | 4.85% | 3.33% | 2.73% | 3.03% |
Free Cash Flow Margin | -11.66% | -3.16% | -15.46% | -1.29% | -1.23% |
EBITDA | 335.17 | 242.43 | 129.58 | 92.78 | 62.85 |
EBITDA Margin | 10.19% | 9.18% | 8.02% | 6.77% | 6.99% |
D&A For EBITDA | 22.42 | 12.92 | 9.62 | 8.46 | 8.22 |
EBIT | 312.75 | 229.51 | 119.96 | 84.31 | 54.62 |
EBIT Margin | 9.51% | 8.69% | 7.42% | 6.15% | 6.08% |
Effective Tax Rate | 30.80% | 25.74% | 27.63% | 26.40% | 26.82% |
Revenue as Reported | 3,300 | 2,672 | 1,628 | 1,374 | 901.56 |